Navigation Links
Breast cancer effectively treated with chemical found in celery, parsley by MU researchers
Date:5/16/2012

COLUMBIA, Mo. Apigenin, a natural substance found in grocery store produce aisles, shows promise as a non-toxic treatment for an aggressive form of human breast cancer, following a new study at the University of Missouri. MU researchers found apigenin shrank a type of breast cancer tumor that is stimulated by progestin, a synthetic hormone given to women to ease symptoms related to menopause.

"This is the first study to show that apigenin, which can be extracted from celery, parsley and many other natural sources, is effective against human breast cancer cells that had been influenced by a certain chemical used in hormone replacement therapy," said co-author Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center.

In the study, Hyder and his colleagues implanted cells of a deadly, fast-growing human breast cancer, known as BT-474, into a specialized breed of mouse. Some of the mice were then treated with medroxyprogesterone acetate (MPA), a type of progestin commonly given to post-menopausal women. A control group did not receive MPA.

Later one group of MPA-treated mice was treated with apigenin. Cancerous tumors grew rapidly in the mice which did not receive apigenin. In the apigenin-treated mice, breast cancer cell growth dropped to that of the control group, and the tumors shrank.

"We don't know exactly how apigenin does this on a chemical level," Hyder said. "We do know that apigenin slowed the progression of human breast cancer cells in three ways: by inducing cell death, by inhibiting cell proliferation, and by reducing expression of a gene associated with cancer growth. Blood vessels responsible for feeding cancer cells also had smaller diameters in apigenin-treated mice compared to untreated mice. Smaller vessels mean restricted nutrient flow to the tumors and may have served to starve the cancer as well as limiting its ability to spread."

The mice in Hyder's study were injected with apigenin. In the future, apigenin injections could be a safe alternative or supplement to the highly toxic chemotherapy drugs now in use.

"Chemotherapy drugs cause hair-loss, extreme fatigue and other side effects," Hyder said. "Apigenin has shown no toxic side-effects even at high dosages. People have eaten it since pre-history in fruits and vegetables."

Finding funding for clinical testing of apigenin in humans may be difficult, according to Hyder.

"Clinical trials of apigenin with humans could start tomorrow, but we have to wait for medical doctors to carry out that next step," Hyder said. "One problem is, because apigenin doesn't have a known specific target in the cancer cell, funding agencies have been reticent to support the research. Also, since apigenin is easily extracted from plants, pharmaceutical companies don't stand to profit from the treatment; hence the industry won't put money into studying something you can grow in your garden."

The research team included Benford Mafuvadze, doctoral student in biomedical sciences; Yanyun Liang, research scientist Dalton Cardiovascular Research Center; Cynthia Besch-Williford, associate professor of veterinary pathobiology; and Xu Zhang, visiting researcher at the Dalton Cardiovascular Research Center.

The research was recently published online in the journal Hormones and Cancer.


'/>"/>

Contact: Timothy Wall
walltj@missouri.edu
573-882-3346
University of Missouri-Columbia
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is ... leading bottled water brand owners that topped the list as a result of their ... conversion. The premier brand was Tibet 5100, a top notch water company that specializes ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
(Date:2/10/2016)... ... February 10, 2016 , ... A national ergonomics ... and Expo event March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, ... As the longest running and largest worker's compensation event in Ohio, organizers of ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... February 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | ... | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016  Visage Imaging Inc. ("Visage"), a ... has announced that the American College of Radiology ... selected the Visage 7 Enterprise Imaging Platform as ... Care Imaging SIMulation (SIM). SIM is the assessment ... (WIDI), a multi-faceted and fully-integrated online assessment, education ...
(Date:2/10/2016)... CORAL SPRINGS, Florida , February 10, 2016 ... Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, ... Medivation, Inc. (NASDAQ: MDVN ), Adamas Pharmaceuticals, Inc. (NASDAQ: ... ). --> Today,s latest Orphan Drug Designations become ... granted by the FDA to novel drugs and biologics which ...
(Date:2/10/2016)... and OR AKIVA, Israel , February ... Ltd., a leader in the field of cartilage ... round on February 5, 2016. The $15 million investment ... a leading Chinese pharmaceutical manufacturer, and was joined by ... Generali Financial Holdings and both the Technion Research & ...
Breaking Medicine Technology: